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Associate Professor, Department of Computer Science
The genetic material we carry today is different from that we were born with since
our cells are prone to mutations. Some mutations can make a cell divide without con-
trol, resulting in a growing tumor – these are called cancer driver mutations. Typically,
in a cancer sample from a patient, a large number of mutations can be detected, and
only a few of those are drivers, which contribute to cancer development. The majority
are passenger mutations that either accumulated before the onset of the disease but
did not cause it, or are byproducts of the genetic instability of cancer cells. One of
the key questions in understanding the process of cancer development is which muta-
tions are drivers, and should be analyzed as potential diagnostic markers or targets for
therapeutics, and which are passengers that do not contribute to oncogenesis.
My research focuses on answering this question by analyzing mutation data from
large groups of cancer patients and using optimization-based approaches to find sets of
genes that fit the characteristic driver mutation pattern of high patient coverage but
low excess coverage. My general approach is to improve state-of-the-art by focusing on
two aspects of optimization-based driver detection: the form of the objective function,
and the techniques for minimizing it.
x
In this work, I present two methods. The first method, QuaDMutEx, incorporates
two novel elements: a new gene set penalty that includes non-linear penalization of
excess mutations in a single patient, and a computationally efficient method for find-
ing gene sets that minimize the penalty through a combination of stochastic search and
exact binary quadratic programming. Compared to state-of-the-art methods, QuaDMu-
tEx algorithm finds sets of putative driver genes that show higher coverage and lower
excess coverage in datasets of mutations from brain, breast and colon tumors. The
second method, QuaDMutNetEx is built on QuaDMutEx method, where I extended
QuaDMutEx by incorporating biological networks as additional source of information
to be taken into account when discovering driver mutations. QuaDMutNetEx has the
ability to discover biologically connected set of driver genes that is also mutually ex-
clusive.
xi
CHAPTER 1
INTRODUCTION
1.1 Motivation
If we live long enough, we will eventually get cancer. That is because our cells are
mutating from the time we are born. Fortunately, not all mutations cause cancer. Only
a small fraction of mutations contribute to oncogenesis, that is, the development of
cancer - these are called driver mutations. Genes in which driver mutations may occur
are called driver genes. The rest of mutations are called passenger mutations and do
not contribute to oncogenesis. Efforts with different approaches are ongoing to delay
or to cure cancer. One important step to beat cancer is understanding its mechanism
and discovering how it starts and progresses. Sequencing the genome of cancer samples
and discovering which of the mutations that are present in it are driver mutations is a
crucial way of doing that.
The Cancer Genome Atlas (TCGA) is an example of a cancer genome sequencing
project. Previous analyses of the data TCGA generated indicate that driver mutations
are scarce. Specifically, depending on the tumor type, a patient can have 10 to more
than 100 passenger mutations in comparison to 2 to 6 driver mutations. The scarcity
of driver mutation among passenger mutations makes it difficult to determine which
mutations are drivers, and multiple approaches are being proposed to offer solution
to this problem. Driver discovery approaches include statistical models, models that
analyze functional impact of mutations, and approaches based on mutual exclusivity
pattern observed in driver mutations. In my work, I adopted the mutual exclusiv-
ity approach. One reason of choosing mutual exclusivity approach is that the other
approaches still suffer from lack of biological information that is necessary to achieve
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reasonable accuracy.
Mutual exclusivity describes the combinatorial pattern of a minimal set of genes
required for oncogenesis. In actual patient data, additional mutations in driver genes
may occur, especially for slow growing tumors or in older patients. Also, some of
mutations may be missed due to observation errors. Thus instead of detecting the
presence or absence of mutual exclusivity in a set of genes, driver detection algorithms
involve a score that penalizes deviations from a driver pattern, that is, a penalty for
zero mutations in a patient, or for more than one mutation. Then, a search procedure
is utilized to find a set of genes closest to mutual exclusivity pattern. It is an NP-hard
problem, thus various approximation algorithms can be proposed.
1.2 Contributions of the Dissertation
My research focuses on improving cancer driver discovery by analyzing mutation
data from large groups of cancer patients, and using optimization-based approaches
to find sets of genes that fit the characteristic driver mutation pattern of high patient
coverage but low excess coverage. My general approach is to improve state-of-the-art
by focusing on two aspects of optimization-based driver detection: the form of the
objective function, and the techniques for minimizing it.
In this work, we present two methods. The first method is QuaDMutEx (Quadratic
Driver Mutation Explorer), a method that incorporates two novel elements. First, in-
stead of a linear penalty for excess coverage used in tools like Dendrix, QuaDMutEx,
uses a quadratic penalty that provides a more realistic penalty for sets with an exces-
sive number of mutations. Second, QuaDMutEx uses a combination of optimal search
through a series of subproblems, allowing for more effective and efficient search through
the space of possible driver genes. In addition, the method allows for user-specified
trade-offs between increasing coverage and decreasing excess coverage allowing for tai-
loring the method to fast- or slow-evolving tumors. In the second method, QuaDMut-
2
NetEx(Quadratic Driver Mutation Network Explorer), we improved the first method
by using preexisting knowledge about which genes interact together in biological pro-
cesses, namely, biological networks of protein-protein interaction. QuaDMutNetEx is
built on top of QuaDMutEx to discover a biologically connected set of driver genes that
are mutually exclusive.
For QuaDMutEx, I evaluated the method on two sources of data. The first source
is The Cancer Genome Atlas, using Glioblastoma Mutiforme (GBM), Breast Invasive
Carcinoma (BRCA) and Colon Adenocarcinoma (COAD) cancers. The second source
of data is from DriverNet method[1], we used four genomic-transcriptomic datasets:
triple negative breast cancer (eTNB), glioblastoma multiforme (eGBM), high-grade
serous ovarian cancer (eHGS), and METABRIC breast cancer (eMTB) datasets.
In the other method, QuaDMutNetEx, we also used two sources of data. the first
one is from DriverNet, namely, eTNB, eGBM, eHGS and eMTB. The other source of
data is a big datset, Pan12, from HotNet2 [2]. Pan12 data set consists of a pool of 12
cancer type. In both data sources we used human protein-protein interactions networks
used in HotNet2, namely, iRefIndex, HINT+HI2012 and MultiNet.
QuaDMutEx shows higher coverage and higher mutual exclusivity than the current
state-of-the-art tool Dendrix. QuaDMutNetEx results in high-quality gene sets that
are known to be biologically connected and have the features of high coverage and high
exclusivity.
1.3 Structure of the Proposal
The rest of the proposal is organized as follows. First, in Chapter 2, I review
relevant facts about cancer and experimental methods for studying it. I also present the
state-of-the-art in methods for discovering cancer driver mutations. Chapter 3 presents
the algorithmic and mathematical background behind my proposed methods, which are
introduced in Chapter 4 and 5. In section 4.3, I present results of using QuaDMutEx on
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different data from TCGA and DriverNet. The same chapters compare QuaDMutEX
to established state-of-the-art methods. In Chapter 5, I present the other method,
QuaDMutNetEx. The discussion of QuaDMutNetEx results and the comparison with
state-of-the-art methods, DriverNet and HotNet2, is in section 5.3.
4
CHAPTER 2
MUTATIONS: BIOLOGY AND BIOINFORMATICS
The study of genes and their variation in humans is important to understand a lot of
diseases including heart diseases, diabetes, hereditary diseases and cancer. There are
multiple ways to study human genetics. One way is through sequencing of the hu-
man genome. This approach has been boosted by the introduction of next-generation
sequencing (NGS) techniques, also known as high-throughput or second-generation se-
quencing. The cost and time required for genome data generation is significantly re-
duced compared to first generation sequencing, also known as Sanger sequencing. In
fact, issues relating to time and cost of sequencing have been replaced with computa-
tional and big data analysis problems. NGS data generated in a week are equivalent to
entire genome centers few years ago. Specifically, a single sequencer can output 40 Gb
per day as opposed to 10 Mb per day in earlier sequencers. This huge growth translates
into the need to process terabytes of data [3]. It also brings the opportunity to better
understand how variations in sequence may impact human health and disease.
2.1 Human Genome Variation
One of the main reasons for genome sequencing is to uncover variation in the human
genome. All human body cells descend from the mitotic cell division of the first fertilized
egg. Dividing cells accumulate a number of alterations in DNA bases compared to that
first fertilized egg. Most DNA damages are repaired except for a small fraction that may
be converted into fixed mutations. Depending on the type of cell the mutations occur,
we differentiate two types of mutations - somatic and germline [4]. Germline mutations
are those occurring in sperm and egg cells - these will be carried on by the parents to
the next generation. Effects of germline mutations, accumulated over generations, are
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partially responsible for the diversity of the human population. Mutations in all other
cells are called somatic mutations - they will not be passed on to offspring, but may
impact the person in which they occur - many will have no detectable impact, but some
may lead to cancer. Projects detecting those mutations are using NGS as a method of
choice. One limitation of NGS technologies is errors in detecting or reading nucleotides
or bases. Hence, given detected mutation in a base discovered by those technologies
needs further analysis and invistigation to decide if the mutation is somatic, germline
or a false positive. Additionally sometimes these errors are missed and classified as a
mutation.
Changes in genetic sequence can be classified into three categories: 1) single nu-
cleotide polymorphisms (SNPs), where a single DNA base is replaced by another; 2)
INDELs (INsertion/DELetion), where between 1 to 10,000 base pairs (bps) are inserted
or deleted from the genome 3) structural variation, where more than 10,000 bps are
inserted or deleted from the genome [5]. Often, SNPs and INDELs involving just one
base pair are called point mutations. These can occur by base substitutions and base
additions or deletions, and may have various impact on the phenotype or protein func-
tions. One simple way to categorize the impact of a point mutation is to look at its
effect on the translated protein sequence of amino acids. Four scenarios are possible: a
silent substitution, missense mutation, nonsense mutation, and a frameshift mutation.
Silent substitution results in a mutation in the DNA sequence with no changes in the
amino acid, hence, no change in the protein function. A missense mutation changes
the amino acid sequence at a single point, that is, results in amino acid substitution.
Nonsense mutations result in a codon that terminates translation, and thus a missense
mutation has a more global effect, leading to a truncated protein. Another type of
mutation with a non-localized effect is frameshift mutation, in which an insertion or a
deletion of a single nucleotide results in change in all the amino acids between the place
of the mutation and the end of the protein [6].
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2.2 Cancer Genome
One of the potential consequences of changes and mutations in the genome is
cancer. Cancer is a complex and heterogeneous disease to which all body organs and
tissues are susceptible. The term cancer is given to any disease in which abnormal cells
divide indefinitely and have the ability to invade other tissues. The American Cancer
Society estimates the diagnosis of 1,735,350 new cases of cancer in the U.S. and cancer
will account for 609,640 deaths in 2018 [7].
Formation of cancer (carcinogenesis) typically involves the following chain of mu-
tations that deregulates cellular proliferation: m1: inactivation of a tumor suppressor
gene results in cell proliferation; m2: mutation(s) that inactivates a DNA repair path-
way; m3: Generation of an oncogene as a result of a mutation in a proto-oncogene;
and m4: mutation(s) that inactivates additional tumor suppressor genes resulting in
cancerous proliferation [8]. Proto-oncogenes are normal genes that control cellular pro-
liferation. A mutation in a proto-oncogene might trigger uncontrolled cellular growth.
In contrast, tumor suppressor genes inhibit tumor formation as the name suggests [9].
2.3 Driver and Passenger Mutations in Cancer
Knowing that cancer arises as an effect of some mutations leads to a question:
which specific mutations contribute to cancer? Depending on their contribution to
cancer development or lack of it, somatic mutations can be divided into two classes,
namely, driver and passenger mutations [4]. Driver mutations, which happen in cancer
genes, perturb normal cell control of proliferation, differentiation and death. Thus,
driver mutations provide survival and growth advantage leading to clonal proliferation of
these mutated cancerous cells [10]. Eventually, these cells may advance to surrounding
tissue and metastasize. Proto-oncogenes and tumor suppressor genes, when mutated,
are called driver mutations. In contrast, passenger mutations, which account for the
majority of somatic mutations, do not confer a growth advantage. It is thought that
7
some of these mutations were already present in the ancestor of the cancer cell when
it acquired any of its driver mutations [10]. Others arise from mutational exposures,
genome instability or from increased cell division that gives rise to a clinically detectable
cancer from a single transformed cell [11]. Cancer genomes can carry up to thousands
of somatic substitutions including driver and passenger mutations [10]. Specifically,
a tissue sample from a cancer patient has on average about 700 mutations in coding
and non-coding regions of the genome, about 130 of them located in the coding region.
Among these 130 mutations, typically only between 2 and 6 are driver mutations [12,
13]. Also, two patients with the same cancer type are likely to have completely different
sets of driver mutations present. Thus, discovering driver mutations responsible for
cancer is difficult due to the coexistence of large number of passenger mutations in the
cancer genome, and high variability of the driver mutations among patients.
2.4 Computational Approaches for the Identification of Driver Genes
Passenger mutations accumulate from the time of egg fertilization to the existing
cancer cell and do not play a role in cancer development. Subsequently, isolating driver
mutations that are important for cancer growth from passenger mutations is often chal-
lenging. In this section we will discuss different approaches to discover driver mutations
and we will provide details of some methods for illustration. In general, there are three
main approaches to discover driver mutations. Namely, functional impact prediction,
recurrent somatic mutation identification and discovery using biological pathways.
2.4.1 Mutation Functional Impact Prediction
This indirect approach applies discovered biological information into protein se-
quences of mutated genes to predict the functional impact of the mutation. If the
predicted impact on protein function is negligible, the mutation is likely to be a pas-
senger. If the impact is high, it may be a potential driver mutation, although in many
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cases the function alternation will not be related to cancer, so it may still be a passen-
ger mutation. Several prediction tools that use different known biological features are
available, including SIFT [14, 15], CHASM [16], Polyphen2 [17] and MutationAssessor
[18]. I present SIFT and Polyphen2 in the next two subsections.
2.4.1.1 SIFT
Conserved proteins are a family of important and essential proteins common be-
tween similar species. SIFT [14, 15] uses the known conserved proteins along with
chemical features of amino acids to predict functional impact of mutations. The soft-
ware assumes that the substitution of an amino acid with one having a reverse chemical
feature may not be tolerated in converved proteins. For instance, if a protein family has
hydrophobic or charged amino acid replaced by a hydrophilic or polar one, respectively,
then SIFT will predict the mutation to have high impact. SIFT predicts the effect
on the protein function by aligning the query protein sequence against related known
protein sequences. Based on how amino acid substitutions at each aligned position in
the related proteins are being tolerated, SIFT gives a probability of whether the substi-
tution in the query sequence is tolerated, and if not, it predicts high functional impact
of the mutation.
2.4.1.2 PolyPhen2
PolyPhen2 [17] is a functional impact prediction tool that uses Naive Bayes clas-
sifier on the distributions of eleven known sequences and structural features that con-
tributes to protein function. Position-Specific Independent Count (PSIC) score is used
in sequence feature calculations. PSIC captures the likelihood of an amino acid to be
in a specific position of protein sequence relying on the distribution of amino acids
in multiple sequence alignments. For structural features PolyPhen2 included the hy-
drophobic properties and whether the amino acid residue can access the surface area of
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the protein. Once the sequence and structural features are calculated, Naive Bayes is
used as a supervised classification method for discriminating tolerated and not tolerated
mutations.
2.4.2 Recurrent Somatic Mutation Identification
One of the most intuitive direct approaches is to consider gene mutation frequency
in observed sequenced cancer samples. In a dataset of cancer samples, driver genes
are expected to accumulate a higher number of mutations than other genes - while
mutations can be seen as a consequence of a random process that does not favor driver
genes, the observed dataset is biased, because it only includes cancer samples, where
mutations in some driver genes did occur in each patient. We can define a baseline
mutation rate, which is simply the expected number of mutated bases per total bases
in a given gene sequence. Features such as gene length, type of mutation, and DNA
sequence context are the main features that impact the background mutation rate.
Subsequently, if a gene exceeds the expected rate given these sequence features, it
is labeled as frequently mutated, and is considered a driver gene. The background
mutation frequency estimation has low accuracy due to the high variability of genome
mutations. Thus, methods that use background mutation frequency tend to include
other factors to improve the accuracy. For instance, MutSig used replication time of
the DNA region and the gene expression level to gain more accuracy of prediction [19]
[20]. We chose two classical tools to elaborate in explaining this approach, namely,
MuSiC [21] and MutSigCV [22].
2.4.2.1 MuSiC
Significantly mutated genes are used to point out genes that show significantly
higher mutation rate than the background mutation rate. MuSiC considers multiple
mutational mechanisms, as well as gene location, to improve calculations of background
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mutation rate. Background mutation rate of a tested sample or a group of similar
samples compared with appropriate background mutation rate and p-value of each gene
produced is then used to decide if a gene is a driver based on the p-value significance
[21].
2.4.2.2 MutSigCV
MutSigCV estimates the background mutation rate with respect to each gene based
on synonymous mutations within the genes and non-coding mutations in surrounding
genes. Background mutation rate suffers from low accuracy, and to obtain more accu-
rate estimation MutSigCV pools data from other genes having similar properties to the
gene of interest. For instance, MutSigCV uses the properties of gene replication time
and expression level as features to improve the estimation accuracy. Finally, p-values
are calculated to determine if the observed mutation in a given gene is not likely random
in comparison to the background model, hence, concluding that the gene is a putative
driver gene in cancer development [22].
2.4.3 Pathway-centric Driver Mutation Discovery
Genes and proteins interact and impact each other through signaling processes,
regulatory interactions, and metabolic reactions. Mutation in a driver gene located
in an important pathway perturbs the pathway, and that perturbation might lead to
cancer. Observations show that cancer development is likely to depend on pathway per-
turbation, which can result from mutation in any gene involved in the pathway, instead
of depending on a mutation in a single specific gene. Knowing that oncogenesis most
likely depends on pathways rather than on particular genes has shifted the direction
towards discovering driver mutation members of pathways instead of individual genes
[23][24].
In general, there are two sub-approaches with respect to biological pathways. The
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first is based on using existing prior knowledge of biological pathways, including the
networks of protein-protein interactions and transcription regulation, and pre-defined
pathways [25, 26, 27, 28, 29]. Three examples of this approach, PathScan, HotNet and
DriverNet are presented below.
The second approach does not use any pathway information, instead it relies on
discovering members of an important cancer-driving pathways de novo from mutation
data, based on a pattern of mutations that would be expected in genes from a single
pathway [30, 31, 32]. This approach is the one being adopted in this work, so below we
explain in detail how Dendrix, a current state-of-the-art method that uses the de novo
approach, works.
2.4.3.1 PathScan
PathScan [24, 25] is an extension of an approach that relies on background mutation
rate that assesses the increase in frequency not for a single gene, but for a whole user-
supplied pathway. Using a whole pathway helps deal with overall low frequency of
driver mutations, and their random distribution among genes in a pathway.
2.4.3.2 HotNet
HotNet [23, 26, 27] aims at detecting sub-networks of genes, where most of the
genes have many mutations. The main problem in this approach is that biological
networks have highly skewed degree distribution, with hub genes that are connected to
many other genes, and may thus be chosen to be part of the sub-networks even if they
are not driver genes. To deal with this problem, HotNet uses a heat or fluid diffusion
model on biological network. HotNet method infuses heat to each gene in proportion
to the frequency of mutation of the gene. The heat then diffuses through the edges
of the network for a certain period of time. Low-degree nodes have limited number of
neighbors to diffuse the heat to and will remain hot if they were highly mutated. On
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the other hand, high-degree nodes diffuse the heat to a large number of neighbors, and
thus will not be able to keep their heat. Observing two highly mutated genes connected
by a single low-degree node is of great interest. It is less interesting to have a single
high-degree node connecting several highly mutated genes. Afterward, the network will
break into small sub-networks according to heat distribution. Sub-networks are then
subjected to novel statistical tests that avoid multiple hypotheses testing for a huge
number of networks, and assessing the possibility of having similar sub-networks by
chance at the same time.
2.4.3.3 DriverNet
DriverNet discover drivers genes by evaluating their effect on gene expression. This
algorithm uses a binary gene mutation data matrix, real-valued gene expression data
and an influence graph. Influence graph is a mix of multiple preexisting biological
knowledge, including protein-protein interaction, gene coexpression and others. Essen-
tially, a given query gene consider driver if it is: a) mutated, b) the mutation affects the
expected gene expression of some genes in multiple patients c) the over-expressed or
under-expressed gene has to be connected to the considered query gene. The problem
is formulated in a bipartite graph where the nodes on the left represent all mutated
query genes and nodes on the right are multiple sets of expression data, where each set
represent a patient. Nodes on the right are labeled if the expression pattern is abnor-
mal. Edge is drawn if a gene in the left partition is known to have interaction with a
gene in the right that is expressed abnormally. DriverNet tries to find genes in the left
partition that are highly connected to the nodes in the right. DriverNet algorithm uses
a greedy approximation algorithm to solve the optimization problem since it is similar
to the minimum set cover problem, which is NP-hard.
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2.4.3.4 Dendrix
In contrast to PathScan, HotNet and related approaches, de novo mutated pathway
discovery operates using only mutation data, that is, a list of mutated genes in a set of
samples from cancer patients, without any a priori knowledge of biological networks or
pathways. The discovery is predicated on the assumptions that only a small number
of driver mutations are present in any given tumor [33], and a set of specific pathways
must be perturbed by driver mutations to cause cancer [9]. These two assumptions
suggest that driver mutations are scarce, a tumor rarely has more than one driver gene
mutated per pathway, and within a pathway different samples might have different
driver genes mutated [23]. Indeed, observations suggest that in many types of tumors,
only one mutation per pathway, or functionally related group of genes, is needed to
drive oncogenesis. Thus, the minimal set of mutated genes required for cancer to
develop would consists of several sets of genes, each corresponding to a crucial pathway
such as angiogenesis. Within each gene set, in each patient exactly one gene would be
mutated. That is, all patients would be covered by a mutation in a gene from the set,
and there would be no coverage overlap, that is, no patient will have more mutations
than one in the genes from the set [24]. This pattern has been often referred to as
mutual exclusivity within a gene set.
The De novo Driver Exclusivity (Dendrix) [31] algorithm summarizes how well
a potential set of genes conforms to the driver mutation pattern by introducing two
quantities, total coverage and coverage overlap:
• Total coverage = number of patients covered by at least one gene from the given
gene set
• Coverage overlap = total count of all mutations in genes from the set that are in
excess of one mutation per patient
These two quantities give rise to a Dendrix score, defined as total coverage minus
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coverage overlap. This score is the objective function that is maximized by Dendrix.
Dendrix uses Markov Chain Monte Carlo approach to maximize it, given a requested
size of the set of genes, typically a number between three and ten.
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CHAPTER 3
TECHNIQUES FOR SOLVING HARD OPTIMIZATION PROBLEMS
As we have seen in Chapter 2.4.3.4, finding driver mutations using de novo pathway-
centric approach involves solving an optimization problem. The approach proposed here
also employs optimization techniques - specifically, techniques for solving binary quan-
dratic programs. Thus, this chapter will provide background on quadratic optimization
including quadratic programming, binary quadratic programming, and heuristic meth-
ods for solving it.
3.1 Optimization with Quadratic Programming
In general, an optimization problem is called quadratic programming if it has con-
vex, quadratic objective function, possibly with a set of affine constraints. A quadratic
program can be expressed in the following form:
minimize
x
1
2x
TQx + cTx + α
subject to Ax ≤ b,
(3.1)
where Q is an element of symmetric n×n positive semidefinite matrices set, or Q ∈ S n+ .
A on the other hand is an element of real m × n matrices set, or A ∈ Rm×n. c is a
vector of coefficients, and x is the unknown real-valued vector that we seek.
3.1.1 Unconstrained Binary Quadratic Programming
In many practical applications, including the one studied here, the vector x we seek
has to be a binary vector, because each member of x has the option be in the solution
set, giving rise to Binary Quadratic Programs. One subclass of these are problems
without constraints: the Unconstrained Binary Quadratic Programs (UBQP). UBQP
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has been used in several applications including graphs and clustering problems. A
UBQP can be represented as:
minimize
x
1
2x
TQx + cTx + α
subject to xi ∈ {0, 1},
(3.2)
where Q ∈ S n+ . UBQPs has been studied since early work by Hammer and Rudeanu in
1968 [34, 35]. Although UBQP looks simple, it is known to be NP-hard [34]. Nonethe-
less, for small problems, the global optimum can be obtain using currently available
solvers such as Gurobi or CPLEX that utilize branch-and-bound approach [34]. For
larger problems, including those from genomics where the number of variables can be
in thousands, solving UBQP requires heuristic methods such as simulating annealing
or genetic algorithms, that do not guarantee optimality of the returns solution. Certain
class of UBQP problems have combinatorial equivalents, and in some cases solving the
UBQP is more efficient than using combinatorial methods [34].
3.2 Heuristics for Solving Unconstrained Binary Quadratic Programs
3.2.1 Genetic Algorithms
Genetic algorithms (GAs) are programming approaches to mimic a simple version
of biological evolution theory towards better fitness, for the purpose of solving scientific
and engineering problems. The majority of GAs methods have at least four funda-
mental elements: dynamically changing chromosome population in which each chromo-
some encodes one solution to the original problem; crossover between chromosomes to
construct new chromosomes; random mutation of new chromosomes; and selection of
chromosomes based on fitness [36]. In the simplest setting, each chromosome is a binary
string encoding a solution. Also, a fitness function is defined to quantify how good the
solution encoded by a chromosome is. Then, GA incorporates three operations: 1) Se-
lection: chromosomes with high fitness values will be selected to produce offspring ; 2)
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Crossover, which produces offspring of two chromosomes by taking parts of chromosome
from each parent and merging them to form a new chromosome; 3) Mutation, in which
the offspring are subject to small random changes. For instance, a crossover between
sequence 11110000 and 10101010 can result in two new chromosomes: 11111010 and
10100000. These can then by mutated by flipping a random bit, resulting in 11111110
and 10110000. We can escape local minima in GAs by using memetic algorithms [37].
memetic algorithms can escape local minima by accepting a less-fit neighbor.
3.2.2 Markov Chain Monte Carlo Algorithms
MCMC was ranked as one of the top 10 most important algorithm in the 20th
century [38]. The goal of the algorithm is to sample from a given distribution p∗(x) by
constructing a Markov chain on the state space χ that has stationary distribution p∗(x).
By drawing enough x0, x1, ..., xn, samples from the chain, we can reach the stationary
distribution p∗ [39].
3.2.2.1 Metropolis-Hastings Algorithm
Metropolis-Hastings algorithm (MH) [40, 41] is a known MCMC method that is
used in multiple applications [42], including finding minima of a black-box function
f(x), where the state space is the domain of the function. The core concept of MH-
based optimization is to design a chain in which points x with low value of the function
correspond to states in the state space that have high probability in the stationary
distribution. Transition from state xi to state xi+1 is achieved by randomly sampling a
new state, and going through accept-or-reject filtering based on the value of the function
at both points. Particularly, we have certainty of accepting the new solution xi+1 if the
value of the function decreases, and low but not null probability to acceptance if the
value of the function increases, which helps to escape the local minima. After enough
number of transitions MH converges into desired stationary distribution, hence, global
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minima are more likely to be sampled[39]. Algorithm 1 illustrates the Metropolis-
Hastings algorithm in more detail.
Algorithm 1 Metropolis-Hastings algorithm
1: Initialize with a solution x1
2: for n← iteration{1, ..., N} do
3: xcand = RandomSolution(xn);
4: Wn = [f(xn)− f(xcand)];
5: Compute p = min[1, eWn ];
6: Sample u ∼ U(0, 1);
7: if u < p then
8: Set xn+1 as xcand
9: else
10: Set xn+1 as xn
11: end if
12: end for
Often, the best solution encountered during the iterations is stored, and returned
instead of the last solution.
3.2.2.2 Simulated Annealing
Simulated annealing is used to find minimum of a black box function f(x). It is
directly related to Metropolis Hastings algorithm in terms of random sampling from
unknown probability distribution. It simulates the effect of annealing, that is heating
and cooling a material to achieve a minimum energy state. For optimization, the value
of the function f(x) takes the role of energy of the state x. At fixed temparature T ,
the algorithm behaves just like the MH algorithm, and x approches samples from a
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stationary distribution with state probabilities:
p(x) ∝ exp(−f(x)/T ). (3.3)
The convergence to the stationary distribution is achieved through randomly sampling a
new state based on the current one, and accepting it or rejecting depending on coefficient
α
α = exp([f(x)− f(x′)]/T ). (3.4)
As in Metropolis Hastings, we accept the new state xt+1 with probability min(1, α).
The chances of accepting an state that is farther from optimum than the current
state depend on the value of the temperature. At high temperature, acceptance of
solutions that are worse than the current one is more likely than at low temperatures.
Simulated Annealing starts with high temprature, to allow for relatively free exploration
of the state space. SA then reduces the temperature gradually, which shifts the behavior
towards accepting better, or only slightly worse solutions, and favors local exploration.
Algorithm 2 shows Simulated Annealing in detail.
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Algorithm 2 Simulated Annealing
1: Initialize with a solution x1
2: for n← iteration{1, ..., N} do
3: xcand = RandomSolution(xn);
4: Wn = [f(xn)− f(xcand)]/T ;
5: Compute p = min[1, eWn ];
6: Sample u ∼ U(0, 1);
7: if u < p then
8: Set xn+1 as xcand
9: else
10: Set xn+1 as xn
11: end if
12: Decrease temperature T
13: end for
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CHAPTER 4
DETECTING DRIVER MUTATIONS USING BINARY QUADRATIC
PROGRAMMING
4.1 Proposed Method
The proposed approach for discovering driver mutations is based on optimization
techniques, and belongs to the category of Pathway-centric Driver Mutation Discovery
methods that were summarized in Chapter 2. I focus on two aspects of optimization-
based driver detection: the form of the objective function, and the techniques for min-
imizing it.
In this proposal, I present Quadratic Driver Mutations Explorer (QuaDMutEx)
[43], a method that incorporates two novel elements: a new gene set penalty that
includes non-linear penalization of excess mutations in a single patient, and a com-
putationally efficient method for finding gene sets that minimize the penalty through
a combination of stochastic search and exact binary quadratic programming. It also
allows for adjusting the desired behavior through parameters that control the solution
size, and the trade-off between coverage and mutual exclusivity.
The proposed algorithm for detecting driver mutations in cancer operates at the
gene level. That is, on input, we are given an n by p mutation matrix G, where n is the
number of cancer patients with sequenced cancer cell DNA, and p is the total number
of genes explored. The matrix is binary, that is, Gij = 1 if patient i has a non-silent
mutation in gene j; otherwise, Gij = 0. A row vector Gi represents a row of the matrix
corresponding to patient i. The solution we seek is a sparse binary vector x of length
p, with xj = 1 indicating that mutations of gene j are cancer driver mutations. In the
proposed approach, the solution vector should capture driver genes that are functionally
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related, e.g. are all part of a pathway that needs to be mutated in oncogenesis. If we
want to uncover all driver genes, we should apply the algorithm multiple times, each
time removing the genes found in prior steps from consideration. We will often refer to
the nonzero elements of x as the mutations present in x.
In designing the algorithm for choosing the solution vector x, we assume that any
possible vector is penalized with a penalty score based on observed patterns of driver
mutations in human cancers. We expect that each patient has at least one mutation
in the set of genes selected in the solution; however, in some cases, the mutation may
not be detected. Also, while several distinct pathways need to be mutated to result
in a growing tumor, typically one mutation in each of those pathways suffices. The
chances of accumulating additional mutations in the already mutated pathway are low
and decrease with each additional mutation. Not all tumors grow at the same pace,
slow-growing tumors have a higher chance of accumulating additional mutations. In
those types of tumors, we needed to have some flexibility to reduce the overlap penalty
to allow some overlaps. We introduce parameter k that capture this decreasing odds
through a quadratic penalty associated with x given the observed mutations Gi in
patient i
L(Gi, x) =
1 + k
2 (Gix− 1)
(
Gix− 21 + k
)
(4.1)
The term Gix captures the number of mutations from solution x present in patient
i. The penalty is parameterized by a non-negative real number k to be chosen by the
user. It captures the ratio of penalty for exactly two mutations from set x present
in patient i to penalty for no mutation from set x present in patient i. We incur no
penalty if the number of mutated genes from x in a given patient is one. The effect of k
on the penalty can be seen in Figure 1. For example, for a tumor with strong mutator
phenotype where more mutations are present one can set k to a low value, lowering the
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penalty for multiple mutations in genes from set x present in a patient.
Figure 1: Effect of different values of k on penalty L(Gi, x), in a function of Gix, i.e.,
the number of mutations from solution x present in patient i. As k gets bigger, the
resulting solution has more preference towards exclusivity
In addition, we expect the number of genes harboring driver mutations in a given
pathway is small. Hence, we introduce a penalty on the number of genes selected in
the solution, in a form of L0 pseudo-norm, L0(x) = ||x||0. The effect of introducing the
penalty can be seen in Figure 2.
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Figure 2: Illustration of the driver selection problem with six genes and four patients.
Without the L0 term, either violet (g1 − g4) or blue (g5, g6) genes are both globally
optimal solutions. Inclusion of L0 pseudo-norm makes the blue solution a preferred
one.
The total penalty for a possible solution vector x is a sum of per-patient penalties
and the solution-size penalty:
L(G, x) = CL0(x) +
n∑
i=1
L(Gi, x). (4.2)
The parameter C controls the trade-off between minimization of L(Gi, x) terms
and of the L0 pseudo-norm. It can alternatively be seen as the penalty incurred by
increasing the number of genes in the solution x by one.
The result of the transformation is an unconstrained binary quadratic problem
with the solution space involving binary vectors x of length p:
minimize
x
xTQx− fTx (4.3)
subject to 0 ≤ x ≤ 1 (4.4)
x ∈ Z (4.5)
where Q = k + 12 G
TG (4.6)
f = k + 32 G
T1n − C1p (4.7)
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where 1n represents a unit vector of length n. Binary quadratic problems are known
to be NP-hard in general [34]. However, the optimal solution can be obtained quickly for
problems of small size. Our approach in solving this problem involves a meta-heuristic
based on Markov-Chain-Monte-Carlo search combined with optimal local search for
small subproblems. The subproblems algorithm is presented below.
The main QuaDMutEx algorithm goes through T iterations, and in each considers
a solution x containing up to ν genes. In each iteration, a new candidate solution
is generated by randomly modifying the current solution vector. The new candidate
solution is then modified by dropping some genes, based on exact binary quadratic
optimization (eq. 4.3) involving ν genes present in the candidate solution. If the
optimized solution is better than the solution from previous iteration, it is accepted. If
not, it is accepted with probability depending on the difference in quality of the previous
and the current solution. Throughout iterations, the solution x∗ with the lowest value
of the objective function (eq. 4.3) is kept.
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Algorithm 3 QuaDMutEx
1: procedure QuaDMutEx(G,C, k, ν, T,Γ, σ)
2: x0 = 0
3: L∗ = L0 =∞
4: for t← 1, ..., T do
5: x=RandomGenerateNewSolution(xt−1, ν,Γ)
6: x, L=LocalOptimizeSolution(G, x, C, k)
7: if L < L∗ then
8: L∗ = L
9: x∗ = x
10: end if
11: P=exp(−L−Lt−1
σ
)
12: r=RandomUniform[0,1]
13: if r < P then
14: Lt = L
15: xt = x
16: else
17: Lt = Lt−1
18: xt = xt−1
19: end if
20: end for
21: return x∗
22: end procedure
The random process generating a new candidate solution based on current solution
always returns a solution with exactly ν genes. If the current solution already has ν
genes, one of them will be randomly replaced with a gene not in the solution. The
gene to be removed is chosen at random with uniform probability of 1/ν. The gene
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to be added is chosen by random sampling from a distribution Γ∼x, which is defined
through a user-supplied distribution Γ over all genes, modified to have 0 probability for
the genes currently in solution x. If the current solution contains less then ν genes, the
solution is expanded to include ν genes, and the ν−||x||0 genes to be added are sampled
without replacement according to Γ∼x. In our experiments, we used Γ proportional to
the logarithm of the frequency of a mutation in a given gene among patients in the
dataset.
Algorithm 4 QuaDMutEx: RandomGenerateNewSolution
1: procedure RandomGenerateNewSolution(x, ν,Γ)
2: if ||x||0 = ν then
3: x=RandomReplaceOne(x,Γ∼x)
4: else
5: x=x + RandomSample(ν − ||x||0,Γ∼x)
6: end if
7: return x
8: end procedure
The local search for an improved new solution returns an optimized solution x
and its penalty score, L. It operates by limiting the problem to the ν genes present
in the new candidate solution. That is, we create a n by ν submatrix Gx by choosing
from G columns for which x = 1. Thus, we have an NP-hard binary QP problem
with small number of variables, which can be solved using standard techniques. In our
experiments, for datasets with below 500 patients, values of ν up to 50 lead to problems
where global optimum could be reached in less than a second on a desktop workstation.
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Algorithm 5 QuaDMutEx: LocalOptimizeSolution
1: procedure LocalOptimizeSolution(G, x, C, k)
2: Gx = SubMatrix(G, x)
3: x, L = BinaryQP(Gx, C, k)
4: return x, L
5: end procedure
4.2 Method Complexity
Preparing the data to be solved by our algorithm is O(n3) that is because of the
quadraic term GTG needed in BQP. Inside the algorithm, generating a new random
solution is O(n). Solving the BQP locally is NP-hard but for small problems, the global
optimum can be obtain using currently available solvers such as Gurobi.
4.3 Results and Discussion
4.3.1 Evaluation on Real Cancer Datasets
Table 1.: Summary of mutation-only datasets used in experimental validation of QuaD-
MutEx.
Dataset samples (n) genes (p) mutations
GBM 84 178 809
OV 316 312 3004
LUNG 163 356 979
BRCA 771 13,582 33,385
We evaluated the proposed algorithm using four somatic mutation datasets (see
Table 1), one from the Cancer Genome Atlas (TCGA) database and three from litera-
ture. Two datasets were originally used by the authors of Dendrix: somatic mutations
in lung cancer (LUNG), and a dataset relating to Glioblastoma Multiforme (GBM)
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that includes not only somatic mutations but also copy number alternations. The ovar-
ian cancer dataset (OV) was originally used by the authors of TiMEx tool [44]. A
larger dataset of mutations in samples from Breast Invasive Carcinoma (BRCA) was
downloaded from TCGA. We have no missing data in any of the datasets. Following
standard practice, in the BRCA dataset we removed known hypermutated genes that
have no role in cancer [45], including olfactory receptors, mucins, and a few other genes
such as titin. For each dataset, each gene in each patient was marked with one if it
harbored one or more mutation, and with zero otherwise, resulting in the input matrix
G for QuaDMutEx.
4.3.2 Quantitative Evaluation of QuaDMutEx Results
We ran QuaDMutEx on the four datasets: GBM, OV, LUNG, and BRCA. In
the tests, we set the maximum size of the gene set to be ν = 30. We set k = 1,
indicating neutral stance with respect to the trade-off between coverage and excess
coverage. The value of C, the weight of the gene solution size penalty, was set to 0.5
for GBM, the dataset with the smallest number of genes measured, to 1 for the LUNG
and OV datasets which have twice the number of genes compared to GBM, and to
1.5 for BRCA, the dataset with much larger number of genes. We ran QuaDMutEx
for 10, 000 iterations, which corresponds to running times below 10 minutes for each
dataset. For GBM and BRCA, we also ran additional experiments with the default
parameter values: k = C = 1.
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Table 2.: Quantitative characteristics of QuaDMutEx results. For all four datasets, the
solutions are statistically significant at p < 0.05.
Dataset Parameters Genes Quadratic penalty Estimated p-value
GBM k = 1, C = 0.5 12 18 0.023
GBM k = C = 1 (default) 7 20.5 0.001
OV k = C = 1 (default) 3 17 0.010
LUNG k = C = 1 (default) 15 59 0.036
BRCA k = 1, C = 1.5 20 393 0.002
BRCA k = C = 1 (default) 26 399 0.002
To assess statistical significance of the results returned by QuaDMutEx, we used
permutation test proposed in [46]. In short, we randomly permuted the contents of each
column of the input patient-gene matrix, which results in randomized dataset in which,
for each gene, the number of patients harboring a mutation in the gene is preserved,
but any pattern of mutation within a row, that is, within each single patient, is lost.
We created 1000 randomized datasets and ran QuaDMutEx on each dataset. The value
of the objective function observed on the original dataset was then compared with the
distribution of objective function values on the randomized datasets to obtain a p-value
estimate. The results of the tests, presented in Table 2, show that for all four datasets,
QuaDMutEx returns gene sets that are statistically significant at 0.05.
The quadratic penalty provides a single-metric measure for what is essentially a
two-criterion optimization problem involving simultaneous maximization of coverage
and mutual exclusivity. To capture each of these independently, we used two metrics,
coverage and excess coverage:
• coverage = number of patients covered by at least one gene from the settotal number of patients
• excess coverage= number of patients covered by more than one gene from the setnumber of patients covered by at least one gene from the set
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These metrics together capture how well a gene set conforms to the pattern expected
of driver genes. Both of the metrics range from 0 to 1. A perfect pattern would have
coverage of 1 and excess coverage of 0, indicating full mutual exclusivity.
4.3.3 Comparison with other Mutual-Exclusivity-based Methods
For comparison, we used RME [47], TiMEx [44], CoMEt [48] and Dendrix [46] as
they are all from the de novo discovery family of methods [49] for driver detection,
and all utilize only genetic data, same as QuaDMutEx. We ran the four tools on
the same four datasets: GBM, OV, LUNG, and BRCA. For TiMEx, which does not
require the user to specify the number of genes in the solution, we ran the tool with
default parameters. Dendrix, RME and CoMEt require the user to provide the desired
solution size. For Dendrix, we performed 29 runs for each dataset, with the solution
size parameter ranging from 2 genes to 30 genes, and picked the solution size with the
best Dendrix score. Each run involved 107 iterations. For CoMEt, the running time
increases steeply with the requested solution size, thus we used sizes for which a single
run finishes in less than 48 hours; in result, we tested solution sizes 2, 3, 4 ,5 for GBM
and OV, between 2 and 6 for LUNG, and between 2 and 10 for BRCA. For RME, we
used solution sizes between 2 and 5 genes, as recommended by the authors of the tool.
For BRCA dataset, RME invoked with default parameters does not return any valid
solution; to circumvent this problem, we executed RME for BRCA with the minimum
gene frequency parameter lowered to 0.02 from the default value of 0.1. For the other
three datasets, we used the default value.
We used the objective function maximized by Dendrix, which can be expressed by
the notation introduced in the Methods section as Dendrix score = n−∑ni=1 |Gix− 1|,
as the metric for evaluating the tool. Essentially, the Dendrix score equals to total
coverage minus coverage overlap, where total coverage is the number of patients covered
by at least one gene from the given gene set, and coverage overlap is total count of all
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mutations in genes from the set that are in excess of one mutation per patient. High-
quality solutions should have high Dendrix score.
The results of the tests, presented in Table 3, show that QuaDMutEx consistently
returns higher quality solutions than all other methods. Only on the OV dataset,
Dendrix discovers the same set of genes as QuaDMutEx. Remarkably, the quality of
solutions from QuaDMutEx is higher even though the score used as the metric, the
Dendrix score, is not function optimized by QuaDMutEx, but is the objective function
of Dendrix. These results show that the proposed optimization scheme that combines
stochastic heuristic approach with exact solution to a series of tractable subproblems is
more efficient than the heuristic approach employed in Dendrix. The putative cancer
driver gene sets discovered by QuaDMutEx are mostly different than sets returned by
other tools (see Figure 3).
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Table 3.: Comparison between QuaDMutEx and other methods. For QuaDMutEx, we
used default parameter values k = 1 and C = 1 unless specified otherwise.
Method Genes Coverage Excess coverage Dendrix score
GBM: Glioblastoma multiforme
TiMEx 3 0.7857 0.0606 62
RME 3 0.7857 0.0606 62
CoMEt 5 0.8452 0.0845 65
Dendrix 9 0.8571 0.0556 68
QuaDMutEx (C=0.5) 12 0.9286 0.0769 72
QuaDMutEx 7 0.8690 0.0822 67
OV: Ovarian Cancer
TiMEx 2 0.9525 0 301
RME 5 0.9494 0.1 62
CoMEt 2 0.9525 0 301
Dendrix 3 0.9557 0 302
QuaDMutEx 3 0.9557 0 302
LUNG: Lung Adenocarcinoma
TiMEx 2 0.5521 0 90
RME 3 0.6748 0.1273 96
CoMEt 6 0.6196 0 101
Dendrix 12 0.6809 0.0270 108
QuaDMutEx 15 0.8160 0.1053 119
BRCA: Breast Invasive Carcinoma
TiMEx 3 0.4202 0.1006 289
RME 3 0.3865 0.0268 290
CoMEt 3 0.2620 0 202
Dendrix 29 0.5811 0.09598 402
QuaDMutEx (C=1.5) 20 0.6109 0.1338 408
QuaDMutEx 26 0.6342 0.1595 411
34
Figure 3: Comparison of putative cancer driver gene sets returned by QuaDMutEx and
the other tools. Genes found by a tool are in dark blue.
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We also checked how QuaDMutEx performs with respect to coverage and excess
coverage, and compared the results with those of Dendrix, RME, TiMEx, and CoMEt.
One of the features of QuaDMutEx is the flexibility in choosing the parameter k, which
controls the trade-off between high coverage but higher excess coverage solutions and
low excess coverage but lower coverage solutions. Thus, we ran QuaDMutEx with a
range of values of parameter k = 0.25, 0.5, 1, 1.5, 2, 2.5, 4. As previously, the value of C
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was set to 0.5 for GBM, to 1 for the LUNG and OV, and to 1.5 for BRCA. The number
of iterations was again set to 10,000. For each parameter setting, we ran QuaDMutEx 5
times. We also gathered results from 5 runs of Dendrix for the best-performing solution
size. For RME, TiMEx, and CoMEt the results do not vary from run to run, so we
instead picked top five solution from a single run. Then, we quantified coverage and
excess coverage. The results in Figure 4 show that QuaDMutEx solutions are on the
Pareto-optimality frontier of all (RME, TiMEx, CoMEt, Dendrix and QuaDMutEx)
solutions. For each Dendrix, TiMEx and CoMEt solution, there is a QuaDMutEx
solution that is better: has higher coverage and lower excess coverage. These results
further confirm results from Table 3 showing that the proposed tool improves upon the
state-of-the-art. Data for OV are not shown graphically, as there is very little variability
in solutions returned by the methods and the plot only confirms what is presented in
Table 3.
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Figure 4: Comparison of results from QuaDMutEx using different values of parameter
k with results from other tools, in terms of coverage and excess coverage: a) GBM; b)
LUNG; c) BRCA. In all three datasets, QuaDMutEx results are on the Pareto frontier.
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4.3.4 Effects of Parameters on QuaDMutEx
The proposed method allows for adjusting the penalty for expanding the solution
size, through a parameter C that corresponds to the additional penalty for increasing the
number of genes in the solution by one. It also allows for tweaking the trade-off between
coverage and mutual exclusivity, through a parameter k that captures the ratio of
penalty for one excess mutation in a patient to penalty for the patient not being covered
by any mutation. We have analyzed how these two parameters affect the solution by
running QuaDMutEx for 10,000 iterations for parameters C = 0.25, 0.5, 1, 1.5, 2, 2.5, 4
and k = 0.25, 0.5, 1, 1.5, 2, 2.5, 4.
Figure 5 shows that the parameter C achieves its design goal, that is, solutions
with higher C include fewer genes. The figures also show that as the penalty for the size
of the solution set is lowered, by specifying lower value of C, the coverage of patients by
genes in the solution tends to increase for the three small datasets, where high values of
C reduce the solution size to only a few genes and thus necessarily lower coverage. This
effect is not present in the large dataset, BRCA, where C does not impact coverage.
Changing C does not show any impact on excess coverage.
Changes in parameter k result in changes in coverage and excess coverage, but
has no substantial impact on the number of genes in the solution. The results show
that, as intended, lower values of k lead to higher coverage, at the cost of higher excess
coverage, than high values of k. Thus, for slow growing tumors, tumors with elevated
mutator phenotypes, or tumors in old patients, where many mutations may occur by
chance and higher excess coverage is expected, low values of k is preferred over high k
values.
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Figure 5: Effects of parameters C and k on QuaDMutEx results, i.e., coverage (a,d,g,j),
excess coverage (b,e,h,k), and genes in solution (c,f,i,l), for GBM dataset (a,b,c), OV
dataset (d,e,f), LUNG dataset (g,h,i), and BRCA dataset (j,k,l).
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4.3.5 Qualitative Assessment of QuaDMutEx Results
To validate the ability of QuaDMutEx to take only mutation data and discover rare
putative cancer driver genes, which are the most hard to find using traditional methods
that rely on mutation frequency in patient population, in each of the four datasets we
focused on the genes in the solution with the fewest number of mutations. See Table 4
for a complete list of all genes in the solution, and for the number of mutations for each
gene in each dataset. In addition to literature review, we also used DriverDBv2 [50],
a database of previously discovered cancer driver genes, to further validate the quality
of QuaDMutEx solutions. The solution set resulting from a bigger or new dataset will
potentially have novel driver genes.
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Table 4.: Putative driver gene sets discovered by QuaDMutEx. For each gene, in
parentheses, we provide the number of patients in the dataset that harbored a mutation
in that gene. Genes in bold are present int the DriverDBv2 [50] database of previously
discovered cancer drivers.
Putative driver genes Estimated
discovered by QuaDMutEx p-value
GBM: Glioblastoma multiforme
CDKN2B (43) TSFM (16) RB1 (10) ERBB2 (7)
ITGB3 TRIM2 WEE1 CHD5 MARK4 CES3 SHH IQGAP1 (1) 0.023
OV: Ovarian cancer
TP53 (299) KRAS (2) RNASE3 (1) 0.010
LUNG: Lung Adenocarcinoma
KRAS (60) STK11 (34) EGFR (30) EPHB1 (4) MAP3K3 (3)
ABL1 PAK6 MAST1 CYSLTR2 RPS6KA6 FES (2)
BAX PIK3C2B RANBP9 RPSA (1) 0.036
BRCA: Breast Invasive Carcinoma
TP53 (194) PIK3CA (138) GATA3 (80) NBPF1 (27)
CTCF (18) ATM (16) FOXA1 (15) TMEM132C (6)
CABIN1 SRGAP2 KIAA1310 (5) CASP8AP2 TSNARE1 (4)
ADCY1 PITX2 PSG11 (3) ANKRD34B KRT14 MSI1 TWISTNB (2) 0.002
In the brain tumor dataset, eight identified genes are each mutated in only 1 out of
84 patients. Out of these, ITGB3 has known role in multiple cancers [51, 52], TRIM2
has tumor suppressing function in ovarian cancer [53] and plays a role in brain, the
source of the analyzed tissue [54], WEE1 is already a target for cancer therapy [55],
and CHD5 is a known tumor suppressor [56]. Changes in expression of MARK4 have
been observed in glioblastomas [57]. While no cancer role has been so far identified
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for carboxylesterase 3 (CES3), it is known to be expressed in the source tissue of our
samples, the brain [58]. SHH gene has been linked to glioma growth [59], as well as to
other cancers [60]. Finally, IQGAP1 is believed to play a role in cell proliferation and
cancer transformation [61].
In the ovarian cancer dataset, KRAS, a known proto-oncogene, was found mutated
in two patient. Eosinophil cationic protein (RNase 3) was found in only one patient.
The protein, while not present in DriverDBv2 and not directly related to oncogenesis,
has cytotoxic activity and was recently shown to inversely affect viability of cancer cell
lines [62] and thus its mutations may affect human tumor growth.
In the QuaDMutEx solution for the lung datasets, six putative cancer driver genes
are each mutated in only two of the 356 patients, and additional four are mutated in
single patients. Among these, role of ABL1 in cancer is well established. PAK6 has been
shown to be involved in prostate cancer [63], and presence of MAST1 mutations has
been detected in lung samples [64]. The expression of CYSLTR2 gene is a prognostic
marker in colon cancer [65]. RPS6KA2 gene is a putative tumor suppressor gene in
ovarian cancer [66], and FES is a known proto-oncogene [67]. BAX is an oncoprotein
with known role in cancers [68], including lung cancer [69]. Mutations in the PIK3C2B
gene were previously observed in lung and other tumors [70, 71]. There is emerging
evidence of a role of RANBP9 gene in lung cancer [72]. The 67-kDA laminin receptor
gene RPSA, while not present in DriverDBv2, is known to play a role in tumor growth
[73, 74].
Among the putative driver genes discovered by QuaDMutEx in the BRCA sam-
ples, nine were mutated in four or fewer of the 771 patients. Two among the genes that
were mutated in more than four patients were not present in the DriverDBv2 database:
NBPF1 and KIAA1310. However, NBPF1 has recently been identified as tumor sup-
pressor gene [75]. KIAA1310 (KANSL3) is a member of KANSL family which plays
a role in cell cycle and reduction of its function is associated with cancer [76]. Of the
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rarely mutated genes, only TSNARE1 gene is likely to be a false positive. CASP8AP2
gene has been previously linked to cancer [77, 78]. No direct role in oncogenesis for
ADCY1 gene has been reported, however it has been found downregulated in osteosar-
comas [79]. PITX2 is a recurrence marker in breast cancer [80]. PSG11 gene has been
shown to be correlated with survival in ovarian cancer [81]. Ankyrin repeat proteins,
though not ANKRD34B specifically, have been previously reported as promoting cancer
development [82]. KRT14 gene dysregulation was recently linked with breast cancer
metastases [83]. MSI1 is putative therapeutic target in colon cancer [84]. TWISTNB
is a component of the RNA polymerase I complex, and while TWISTNB gene has
not been previously linked to cancer, mutations in polymerase subunits, cofactors, and
mediators are known factors in malignancy [85]. Together, these results confirm that
QuaDMutEx is effective in identifying cancer driver mutations even if they are rare in
the analyzed patient group.
4.3.6 Comparison with Gene Expression-based Driver Discovery
In addition to methods that use only genomic mutation data, we also compared
QuaDMutEx to DriverNet [1], a method that uses a biological network and gene ex-
pression data in addition to mutation data. We used four genomic-transcriptomic
datasets that are provided with the DriverNet tool: triple negative breast cancer
(eTNB), glioblastoma multiforme (eGBM), high-grade serous ovarian cancer (eHGS),
and METABRIC breast cancer (eMTB) datasets. The summaries of the datasets are
provided in Table 5.
DriverNet was executed using default parameters on the full information contained
in the dataset, that is, the genomic, transcriptomic, and biological network information.
The solution gene sets include all genes found by DriverNet to be statistically significant
at the 0.05 p-value threshold. QuaDMutEx was executed using only the genomic data
describing presence or absence of a mutation in a given gene in a given patient. We
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Table 5.: Summary of genomic-transcriptomic datasets used in comparison with Driver-
Net.
Dataset samples (n) genes (p) mutations
eTNB 94 4594 6007
eGBM 120 3747 8141
eHGS 316 13278 22897
eMTB 696 13076 51255
used the default value of k = 1, and set the value of C to 1.5, with the exception of the
smallest dataset, eTNB, for which we used C = 1. We compared the putative cancer
driver gene sets discovered by the two tools using coverage, excess coverage, and the
Dendrix score, as described above.
For the eGBM dataset, QuaDMutEx shows much higher coverage and much lower
excess coverage (see Table 6). For the other three datasets, QuaDMutEx shows much
lower excess coverage than DriverNet, at the cost of a moderate decrease in coverage.
These results reflect the fact that DriverNet is not designed to take mutual exclusivity
of genes into consideration. On the other hand, DriverNet return many more genes
than QuaDMutEx. A single run of QuaDMutEx is designed to return a single set of
genes with low excess coverage, and does not include all putative driver genes - these
can be detected with another run of QuaDMutEx.
To provide a comparison that does not involve mutual exclusivity, we used the
COSMIC database of mutations in cancer, and we introduced iterated QuaDMutEx,
which increases the number of genes found by QuaDMutEx to the numbers similar to
DriverNet. We performed four executions of QuaDMutEx, after each run removing
the genes discovered so far from the dataset, so that they do not prevent discovery
of additional genes that are not mutually exclusive with previously discovered ones.
We then pooled the four high-exclusivity gene sets into a single high-coverage set.
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Table 6.: Comparison between QuaDMutEx and DriverNet.
Method Genes Coverage Excess coverage Dendrix score
eTNB: Triple negative breast cancer
DriverNet 64 0.6809 0.4688 18
QuaDMutEx (C=1) 16 0.8315 0.0270 72
eGBM: Glioblastoma multiforme
DriverNet 19 0.9412 0.8839 -183
QuaDMutEx (C=1.5) 6 0.8067 0.0938 87
eHGS: high-grade serous ovarian cancer
DriverNet 77 0.9430 0.6946 -110
QuaDMutEx (C=1.5) 14 0.8734 0 276
eMTB: METABRIC breast cancer
DriverNet 92 0.4670 0.7785 -1151
QuaDMutEx (C=1.5) 18 0.4071 0.0876 250
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Since mutual exclusivity can be expected only for a set of functionally-related genes,
for example genes from a single cancer-related pathway, a single call to QuaDMutEx
corresponds to a single-pathway query, and calling QuaDMutEx iteratively corresponds
to a multi-pathway query, facilitating comparison with DriverNet which does not have
a single-pathway focus.
Figure 6: Complementary cumulative distribution function plots for QuaDMutEx, it-
erated QuaDMutEx, and DriverNet, for eTNB (a), eGBM (b), eHGS (c), and eMTB
(d) datasets.
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To measure the quality of solutions returned by DriverNet and iterated QuaDMu-
tEx in a way independent of any mutual exclusivity of gene mutations, we compared
the numbers of COSMIC occurrences of mutations in genes returned by DriverNet with
occurrence numbers for QuaDMutEx gene sets. Specifically, for each gene in a discov-
ered gene set, we queried COSMIC for the number of observed mutations in that gene.
We then plotted a complementary cumulative distribution function (CCDF) over the
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numbers over the whole gene set. For example, for the eHGS dataset, for both QuaD-
MutEx and DriverNet, the CCDF value at 1,000 is approximately 0.14, indicating that
for both methods, 14% of the genes in the solution set have more than 1,000 mutation
each in COSMIC, while for 86% of genes in the solution set a COSMIC query for the
gene results in at most 1,000 mutations. The results in Figure 6 indicate that iterated
QuaDMutEx and DriverNet perform similarly on eTNB and eGBM datasets, and on
eHGS and eMTB both perform similarly for majority of the mutation counts range,
with DriverNet having an edge at the numbers below that threshold.
Genes returned by QuaDMutEx are to large extent different than those returned by
DriverNet (see Figure 7), showing that the expression-based approach used in Driver-
Net and the mutation-only approach used in QuaDMutEx are complementary. We
validated the genes discovered by QuaDMutEx (Table 7) in DriverDB2, a database
of genes previously discovered as cancer drivers. For eTNB and eGBM datasets, all
the genes discovered by QuaDMutEx are present in DriverDB2 database. In eHGS
dataset, only ANKRD36B was not found in DriverDB2. However, ANKRD36B gene
was identified in rare germline copy number variations in renal clear cell carcinoma [86],
and also correlates with cellular sensitivity to chemotherapeutic agents [87]. In eMTB
dataset, TRA@ gene is not present in DriverDB2, but it has been previously found to
be linked to breast cancer [88]. TRA@ is also one of the genes that were discovered
both by DriverNet and by QuaDMutEx. TBC1D3P2 is recurrently mutated in menin-
gioma cell lines [89] and is a pseudogene for TBC1D3, a known oncogene [90]. There
is no information available about AC116655.7-12 and AC116165.7-3, and at this point
we classify both as false positives.
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Figure 7: Comparison of putative cancer driver gene sets returned by QuaDMutEx,
iterated QuaDMutEx, and DriverNet. Genes found by a tool are in dark blue.
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POLR1A 
PNMT 
PLCG2 
PIK3R1 
PIGL 
PCK1 
PAPSS2 
PAK1 
OR8G1 
OR2AT4 
NR4A1 
NFATC2 
NDUFC2 
MYC 
MTAP 
LSM1 
JAK2 
ITPR1 
IKBKB 
IDO2 
HSPA8 
HEXB 
GTF2E2 
GRB2 
GNAS 
GALNTL4 
FGFR1 
EP300 
EIF4EBP1 
EGFR 
DHODH 
CSNK2A1 
CSF3 
CREBBP 
COX6B2 
COX11 
CNGB1 
CLTC 
CDKN2A 
CDH1 
CD40LG 
CCNE1 
CCND1 
CBL 
CAT 
CACNB1 
ASAH1 
AMD1 
ALG5 
ADRB3 
ADRA1A 
ADK 
ZNF703 
ZNF630 
ZNF276 
ZNF217 
WWC3 
WHSC1L1 
UBE3A 
TUBGCP5 
TBC1D20 
TARS2 
STARD3 
SOX12 
SORBS1 
SLC2A3 
RSF1 
RAB11B 
PTPRT 
PSG6 
PSG5 
PSG11 
NARS2 
MBD3L1 
INTS2 
HISPPD2A 
GRID2 
GOLPH3L 
GAB2 
ESPNP 
ENSA 
EDAR 
DNMT3A 
CYFIP1 
CYCS 
CTNNA3 
CSH1 
C10orf59 
ANTXRL 
AL357673.12 
AFDC1 
PFDN4 
MDM2 
MAP2K4 
IGF1R 
GRB7 
ERBB2 
BRF2 
TRA@ 
TBC1D3P2 
SLC35F3 
RTF1 
PSG1 
LANCL2 
ITSN2 
DEFB126 
CTSK 
CLNS1A 
C20orf133 
C17orf37 
BCAS1 
ALOXE3 
AC116655.7­12 
AC116165.7­3 
PTEN 
BAG4 
eMTB
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Table 7.: Putative driver gene sets discovered by QuaDMutEx. For each gene, in
parentheses, we provide the number of patients in the dataset that harbored a mutation
in that gene. Genes in bold are present in the DriverDBv2 [50] database of previously
discovered cancer drivers.
Putative driver genes Estimated
discovered by QuaDMutEx p-value
eTNB: Triple negative breast cancer
TP53 (35) PARK2 (6) ROBO2 DUSP22 (4)
SAGE1 ANKRD11 NR3C1 (3) BAP1 BRAF ATG7 (2)
ZNF257 IDH3B ZNF826 RP11-119B16.1 PSG5 MSR1 (2) 0.001
eGBM: Glioblastoma multiforme
CDKN2B (52) TP53 (38) NUP107 (9) HLA-E SAC SPRED3 0.001
eHGS: high-grade serous ovarian cancer
TP53 (249) GLI1 (3) ABHD6 CHMP4A EP400 EPS8L3 FRMD1 (2)
GPATCH8 MCM4 GFRA1 LPPR4 PTK2 WRN ANKRD36B (2) 0.001
eMTB: METABRIC breast cancer
C17orf37(MIEN1) (82) BAG4 (52) CLNS1A (37) PSG1 (24)
C20orf133(MACROD2) (19) BCAS1 (17) PTEN(16) RTF1 ALOXE3 (7)
TRA@ AC116165.7-3 (6) TBC1D3P2 (5) CTSK AC116655.7-12 LANCL2 (4)
ITSN2 (3) DEFB126 (3) SLC35F3 (2) 0.001
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4.3.7 Stability test
To evaluate the stability of our method to see how the resulted objective function
values are close to each other, we repeated our method on GBM data for 100 times
with c = 1.5 and k = 1 10,000 iterations each. Figure 8 shows that the objective
function values were stable and centered in the middle distribution with a mean equal
to 146.1 and a standard deviation equal to 1.75. Since the objective function values
were stable, the coverage and excess coverage were stable as well. Figure 8 also show a
stable distribution for both coverage and excess coverage.
Figure 8: Shows the distribution of the percentage of the genes coverage.
4.4 Conclusions
Superior ability to improve on both coverage and excess coverage of the detected
driver gene sets on datasets from different types of cancer shows that QuaDMutEx is
a tool that should be part of a state-of-the-art toolbox in the driver gene discovery
pipeline. It can help detect low-frequency driver genes that can be missed by existing
methods.
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CHAPTER 5
DETECTING DRIVER MUTATIONS USING BINARY QUADRATIC
PROGRAMMING AND BIOLOGICAL NETWORKS
QuaDMutEx shows that an improved objective function and improved optimization
method can both lead to improvement in detecting driver genes. However, it follows
the de novo approach, which does not take advantage of existing prior knowledge. In this
chapter, I propose a new method, QuaDMutNetEx, into which I integrated additional
terms into the objective function that are present protein-protein interactions. Proteins
perform almost all biological functions within the cell. Hence, using protein-protein
interactions gives a comprehensive image of cellular processes, which lead to a better
interpretation of any results in the context of the cellular system [91].
5.1 Integration of Biological Networks
Genes are elements of a complex system, a cell. One way to represent this complex
system is through networks or graphs. These networks capture prior knowledge about
interactions between genes, or their product, proteins. Since cancer is thought to be
a disease of pathways, in which pathway functioning is perturbed by mutations, using
information about edges forming those pathways in the algorithm will likely improve
driver gene detection. If a gene in a given pathway is a driver, that would increase the
chances that other genes in that pathway are also drivers
5.1.1 Biological Networks
Graphs are one way to represent complicated systems such as social, biological,
and computer networks. Although the exact connectivity of biological networks is not
fully known yet, their analysis and visualization are essential to understanding such a
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complicated system. DNA, RNA, proteins and metabolites interact with each other and
play different roles in biological systems. Therefore, different biological networks exist
to illustrate different levels of biological interactions. For instance, gene regulatory
networks explain regulation of protein production by gene activation and repression
at any given time. On the other hand, protein-protein interaction networks show a
more general view of which proteins make functional complexes with other proteins
to facilitate biological processes including gene expression or cell growth. Metabolic
networks are another type of biological networks that represent chemical substances
transformation from one form to another [92].
In QuaDMutNetEx we used the three human protein-protein interactions networks
previously used in HotNet2 [2]. The first network is the iRefIndex network, which
consists of 91,872 interactions among 12,338 proteins. The second network is Multi-
Net network which consists of 109,597 interactions among 14,445 proteins. The last
network is HINT+HI2012 which is created by considering two interactome databases:
HI-2012 prepublication data in human HI2 Interactome database (HI2012) and high-
quality interactomes database (HINT). The HINT+HI2012 network consists of 40,783
interactions among 10,008 proteins.
5.2 Proposed Method
The aim of my second method is to include protein-protein interactions in the
objective function. The external knowledge carried in the network helpes not only in
improving the algorithm but also in the interpretability of the resulting gene set. The
network can be introduced in various ways. In our method, we introduce the network
as a term N(A, x) that works as a reward term to the objective function if two genes in
a solution are connected. Here, x is the gene solution set and A is the network, encoded
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as an undirected adjacency matrix:
Aij =

1 if gene i is the immediate neighbor of gene j or vice versa,
0 otherwise.
(5.1)
The additional term N(A, x) will be defined as −xTAx. N(A, x) can be expanded
as −∑i,j Aijxixj, where xi and xj are binary. Thus, adding a negative term to the
objective function corresponds to providing a reward every time two genes, xi and xj
in the solution vector x are connected by an edge, that is, when Aij = 1.
Frurther, we added parameter α to the term N to control the reward size. A high
value of α results in a solution set with more connected genes. Therefor, the reward
term N is now updated to be −xTαAx.
The quadratic term −xTαAx can be integrated to the QuaDMutEx objective func-
tion (eq. 4.2) to have a new objective function as follow:
L(G,A, x) =
n∑
i=1
L(Gi, x) + CL0(x) +N(A, x) (5.2)
=
n∑
i=1
1 + k
2 (Gix− 1)
(
Gix− 21 + k
)
+ C||x||0 − αxTAx. (5.3)
Minimization of L(G,A, x) can be viewed as an unconstrained binary quadratic
problem (BQP) with the solution space involving binary vectors x of length p:
minimize
x
xTQx− fTx (5.4)
subject to 0 ≤ x ≤ 1 (5.5)
x ∈ Z (5.6)
where Q = k + 12 G
TG− αA (5.7)
f = k + 32 G
T1n − C1p (5.8)
BQPs are known to be NP-hard in general [93]. Except for the new parameters,
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we used the same algorithm of QuaDMutex to solve this problem, i.e., a meta-heuristic
based on Markov-Chain-Monte-Carlo search combined with optimal local search for
small subproblems. The algorithm is presented below.
The main QuaDMutNetEx algorithm goes through T iterations, and in each con-
siders a solution x containing up to ν genes. In each iteration, a new candidate solution
is generated by randomly modifying the current solution vector. The new candidate
solution is then modified by dropping some genes, based on exact binary quadratic opti-
mization (eq. 5.2) involving ν genes present in the candidate solution. If the optimized
solution is better than the solution from previous iteration, it is accepted. If not, it is
accepted with probability depending on the difference in quality of the previous and
the current solution. Throughout iterations, the solution x∗ with the lowest value of
the objective function (eq. 5.1) is kept.
The random process generating a new candidate solution based on current solution
always returns a solution with exactly ν genes. If the current solution already has ν
genes, one of them will be randomly replaced with a gene not in the solution. The
gene to be removed is chosen at random with uniform probability of 1/ν. The gene
to be added is chosen by random sampling from a distribution Γ∼x, which is defined
through a user-supplied distribution Γ over all genes, modified to have 0 probability for
the genes currently in solution x. If the current solution contains less than ν genes, the
solution is expanded to include ν genes, and the ν−||x||0 genes to be added are sampled
without replacement according to Γ∼x. In our experiments, we used Γ proportional to
the logarithm of the frequency of a mutation in a given gene among patients in the
dataset.
The local search for an improved new solution returns an optimized solution x
and its penalty score, L. It operates by limiting the problem to the ν genes present
in the new candidate solution. That is, we create a n by ν submatrix Gx by choosing
from G columns for which x = 1. Similarly, we create Ax from A by selecting rows
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Algorithm QuaDMutNetEx
1: procedure QuaDMutNetEx(G,A,C, k, α, ν, T,Γ, σ)
2: x0 = 0
3: L∗ = L0 =∞
4: for t← 1, ..., T do
5: x=RandomGenerateNewSolution(xt−1, ν,Γ)
6: x, L=LocalOptimizeSolution(G,A, x, C, k, α)
7: if L < L∗ then
8: L∗ = L
9: x∗ = x
10: end if
11: P=exp(−L−Lt−1
σ
)
12: r=RandomUniform[0,1]
13: if r < P then
14: Lt = L
15: xt = x
16: else
17: Lt = Lt−1
18: xt = xt−1
19: end if
20: end for
21: return x∗
22: end procedure
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Algorithm QuaDMutNetEx: RandomGenerateNewSolution
1: procedure RandomGenerateNewSolution(x, ν,Γ)
2: if ||x||0 = ν then
3: x=RandomReplaceOne(x,Γ∼x)
4: else
5: x=x + RandomSample(ν − ||x||0,Γ∼x)
6: end if
7: return x
8: end procedure
and columns with x = 1. Thus, we have an NP-hard binary QP problem with number
of variables small enough that problem can be quickly solved to the optimum using
standard techniques.
Algorithm QuaDMutNetEx: LocalOptimizeSolution
1: procedure LocalOptimizeSolution(G,A, x, C, k, α)
2: Gx, Ax = SubMatrix(G,A, x)
3: x, L = BinaryQP(Gx, Ax, C, k, α)
4: return x, L
5: end procedure
In the proposed approach, the solution vector x from a single run of QuaDMut-
NetEx will capture a set of driver genes not only functionally related but also exhibit
mutual exclusivity pattern, for example genes that are all part of a pathway that needs
to be mutated in oncogenesis. To uncover a comprehensive set of driver genes for a
specific cancer type, spanning multiple functional subsystems vital to oncogenesis, the
algorithm should be applied multiple times, each time removing the genes found in
prior runs from consideration.
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5.3 Results and Discussion
5.3.1 Evaluation on Real Cancer Datasets
We evaluated the proposed algorithm using five new datasets. Four datasets are
genomic-transcriptomic, that are provided with the DriverNet tool: triple negative
breast cancer (eTNB), glioblastoma multiforme (eGBM), high-grade serous ovarian can-
cer (eHGS), and METABRIC breast cancer (eMTB) datasets. These data set have used
in chapter 4 to evaluate QuaDMutEx. In the fifth dataset, we used Pan12 dataset from
Hotnet2, which consists of 12 cancer types from The Cancer Genome Atlas (TCGA)
[2]. We chose datasets from the tools that we wanted to compare our method with.
That would obtain a better comparison as some discovered networks in those datasets
are already evaluated by those tools. Also, DriverNet uses expression data, which we
do not have in previous method dataset. The summaries of the datasets are provided in
(see Table 8). We have no missing data in any of the datasets. Following standard prac-
tice, we removed known hypermutated genes that have no role in cancer [45], including
olfactory receptors, mucins, and a few other genes such as titin. For each dataset, each
gene in each patient was marked with one if it harbored one or more mutation, and
with zero otherwise, resulting in the input matrix G for QuaDMutNetEx.
Table 8.: Summary of mutation-only datasets used in experimental validation of QuaD-
MutNetEx.
Dataset samples (n) genes (p) mutations
eTNB 94 4594 6007
eGBM 120 3747 8141
eHGS 316 13278 22897
eMTB 696 13076 51255
Pan12 3281 19325 518742
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5.3.2 Quantitative Evaluation of QuaDMutNetEx Results
We ran QuaDMutNetEx on the five datasets: eTNB, eGBM, eHGS, eMTB and
Pan12. As with QuaDMutEx, we set the maximum size of the gene set to be ν = 50.
We set k = 1, indicating neutral stance with respect to the trade-off between coverage
and excess coverage. The value of C, the weight of the gene solution size penalty, was
set to 1.5 to limit the number of genes in the solution set. We experimentally set the
network parameter to α = 0.15. We ran QuaDMutNetEx for 100, 000 iterations, which
corresponds to running times below 30 minutes for all datasets except the big dataset
Pan12, which took 60 minutes to finish the run. Finally, the whole problem with all p
genes can be run in a solver such as Gurobi, which uses a linear-programming based
branch-and-bound algorithm to solve these family of problems. Gurobi has the option
to run the problem for a certain amount of time which results in a solution and lower
and upper bounds. Noticeably, Subproblems solution is much better than a solution
generated by running the whole problem in Gurobi for one day. Also, the lower bound is
a negative value, which can not be interpreted or compared to the current best solution.
As in QuanDMutEx method, we used permutation test proposed in [46] to assess
statistical significance of the results returned by QuaDMutNetEx. In short, we ran-
domly permuted the contents of each column of the input patient-gene matrix, which
results in randomized dataset in which, for each gene, the number of patients harboring
a mutation in the gene is preserved, but any pattern of mutation within a row, that
is, within each single patient, is lost. We created 1000 randomized datasets and ran
QuaDMutNetEx on each dataset. The value of the objective function observed on the
original dataset was then compared with the distribution of objective function values
on the randomized datasets to obtain a p-value estimate. The results of the tests, pre-
sented in Table 9 show that eGBM, eHGS, eMTB and Pan12 datasets,returns gene sets
that are statistically significant at 0.05. eTNB results in gene set with p-value = 0.0634
, which is slightly higher than 0.05
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Table 9.: Quantitative characteristics of QuaDMutNetEx results. Parameters were set
to default, i.e, k = 1, C = 1.5, α = 0.15. Except eTNB, all datasets solutions are
statistically significant at p < 0.05.
Dataset Genes Quadratic penalty Estimated p-value
eTNB 23 54 0.0634
eGBM 6 89 0.0175
eHGS 25 263 0.0019
eMTB 26 285 0.0000
Pan12 25 1894 0.0000
5.3.3 Comparison with other Methods
For comparison, we used DriverNet and HotNet We ran the three tools on the
same five datasets: eTNB, eGBM, eHGS, eMTB and Pan12. For both tools we used
the default values.
DriverNet and HotNet were executed using default parameters on the full infor-
mation contained in the dataset, that is, the genomic, transcriptomic, and biological
network information for DriverNet and only genomic and biological network informa-
tion for HotNet.We used the default value of α = 0.15, k = 1, and set the value of C
to 1.5. We compared the putative cancer driver gene sets discovered by the three tools
using coverage, excess coverage as described in QuaDMuteEx.
We used the objective function maximized by Dendrix to provide a comparison
that is independent and involve mutual exclusivity, which can be expressed as Dendrix
score = n − ∑ni=1 |Gix − 1|, as the metric for evaluating the tool. Essentially, the
Dendrix score equals to total coverage minus coverage overlap, where total coverage
is the number of patients covered by at least one gene from the given gene set, and
coverage overlap is total count of all mutations in genes from the set that are in excess
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of one mutation per patient. High-quality solutions should have high Dendrix score.
The results of the tests, presented in Table 10 show that QuaDMutEx consistently
returns higher quality solutions than DriverNet and HotNet. For the eGBM dataset,
QuaDMutNetEx shows the same coverage and much lower excess coverage. For all
datasets, QuaDMutNetEx shows much lower excess coverage than DriverNet and Hot-
Net, at the cost of a moderate decrease in coverage. These results reflect the fact that
DriverNet and HotNet are not designed to take mutual exclusivity of genes into con-
sideration. On the other hand, DriverNet and NotNet return many more genes than
QuaDMutNetEx. A single run of QuaDMutNetEx is designed to return a single set of
genes with low excess coverage, and does not include all putative driver genes - these
can be detected with several iterations of QuaDMutNetEx. Accordingly, we introduced
iterated QuaDMutNetEx, which increases the number of genes found by QuaDMutNe-
tEx to the numbers similar to DriverNet and HotNet. We performed four executions of
QuaDMutNetEx, after each run removing the genes discovered so far from the dataset,
so that they do not prevent discovery of additional genes that are not mutually exclu-
sive with previously discovered ones. We then pooled the four high-exclusivity gene sets
into a single high coverage set. Since mutual exclusivity can be expected only for a set
of functionally-related genes, for example genes from a single cancer-related pathway,
a single call to QuaDMutNetEx corresponds to a single-pathway query, and calling
QuaDMutNetEx iteratively corresponds to a multi-pathway query, facilitating compar-
ison with DriverNet which does not have a single-pathway focus. Genes returned by
QuaDMutNetEx are to large extent different than those returned by DriverNet. Fig-
ure 9 shows that approaches used in DriverNet and HotNet are complementary to the
approach used in QuaDMutNetEx.
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Table 10.: Comparison between QuaDMutNetEx, HotNet and DriverNet. C=1.5, K=1,
α=0.15 .
Method Genes Coverage Excess coverage Dendrix score Quadratic penalty
eTNB: Triple negative breast cancer
HotNet2 128 0.6809 0.7969 -118 1330.30
DriverNet 21 0.6383 0.4667 23 118.6
QuaDMutNetEx 23 0.6809 0.1563 54 70.88
eGBM: Glioblastoma multiforme
HotNet2 37 0.7833 0.4149 10 368.10
DriverNet 17 0.9333 0.8661 -140 806.6
QuaDMutNetEx 6 0.7667 0.0326 89 39.86
eHGS: high-grade serous ovarian cancer
HotNet2 58 0.8449 0.4307 83 1040.4
DriverNet 72 0.9335 0.6373 -35 1310.3
QuaDMutNetEx 25 0.8291 0.0878 263 122.54
eMTB: METABRIC breast cancer
HotNet2 224 0.4424 0.7394 -1694 61393
DriverNet 90 0.4683 0.7785 -1130 14966
QuaDMutNetEx 26 0.4582 0.1038 285 447.72
Pan12: TCGA pan-cancer of 12 cancer types
HotNet2 136 0.6809 0.7290 -5235 138640
DriverNet NA NA NA NA NA
QuaDMutNetEx 25 0.6586 0.1191 1894 1434.30
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Figure 9: Comparison of putative cancer driver gene sets returned by QuaDMutNetEx,
iterated QuaDMutNetEx, and DriverNet. Genes found by a tool are in dark blue.
Genes do not exsist in both DriverNet and HotNet are removed
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EMR3 
ELOVL3 
DUSP9 
DNAH11 
DMD 
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CD163L1 
CACNA2D1 
C1orf113 
ADCY2 
ADAR 
ABHD8 
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RUFY1 
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OSBPL1A 
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KLHL9 
ITGA10 
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C1orf173 
C14orf39 
AP000351.3.3 
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ABCC1 
HGS
QuaDMutEx(iter.) QuaDMutEx Hotnet DriverNet
TUBB3 
TNFRSF10B 
RPS6KB1 
PTK2B 
PPP2CB 
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ZNF346 
VCX2 
TSKU 
TRDV2 
TMBIM4 
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SORBS3 
SIRPB2 
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PRODH 
POLR3K 
NEGR1 
MAGEB10 
LINS1 
IKZF3 
GPR124 
DOK5 
DNAH9 
DDX19A 
CREB5 
C6orf190 
C1orf21 
C17orf37 
C11orf67 
BCAS1 
AVEN 
AC006970.6 
TLK2 
SCARA5 
PSG1 
PKIA 
PFDN4 
KCTD14 
DDX43 
CSNK2A1 
CCT8 
C16orf91 
AL357673.12 
AC091565.10­1 
GRB7 
METABRIC
5.3.4 Effects of Parameters on QuaDMutNetEx
The proposed method prefer solutions with connected genes. The model gives a
negative rewards to the objective function if it has connected solution. The reward
can be adjusted by parameter α, which leads to intresting behavior with respect to
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covarage and overlap that controls by parameters C and k. Parameter C corresponds
to the additional penalty for increasing the number of genes in the solution by one, and
parameter k captures the ratio of penalty for one excess mutation in a patient to penalty
for the patient not being covered by any mutation. We analyzed how these parameters
affect the solution by running QuaDMutNetEx for 100,000 iterations with fixed k = 1
and parameters α = 0, 0.01, 0.05, 0.1, 0.15, 0.3, 0.5 and C = 0.25, 0.5, 1, 1.5, 2. Also, we
analyzed the effect on the solution set if we set C = 1.5 and varies n and k as follows,
α = 0, 0.01, 0.05, 0.1, 0.15, 0.3, 0.5 and k = 0.25, 0.5, 1, 1.5, 2.
Figure 10 shows that the parameter α achieves its design goal, that is, solutions
with higher α include fewer connected components and prefer connected network. The
α parameter has the following effect on coverage and excess coverage: As the value of
α increases, the coverage decreases and the excess coverage increases. Furthermore, as
the value of α increases, it decreases the effect of C and k. Setting α to a low value,
such as 0.001, makes the effect of C and k to be more dominant. Specifically, increasing
C leads reduce the solution size to only a few genes and thus necessarily lower coverage,
whereas, lowering the value of C leads increase the coverage of patients by increasing
the genes in the solution set. On the other hand, results in changes in parameter k
result in changes in coverage and excess coverage. Specifically, lower values of k lead to
higher coverage, at the cost of higher excess coverage, than high values of k.
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(a) (b)
(c) (d)
(e) (f)
Figure 10: Effects of parameters on QuaDMutNetEx. (a), (b) Effect on connected
components. (c), (d) Effect on coverage. (e), (f) Effect on excess covarage.
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5.3.5 Qualitative Assessment of QuaDMutNetEx Results
To validate the ability of QuaDMutNetEx to take only mutation data and discover
rare putative cancer driver genes, which are the most hard to find using traditional
methods that rely on mutation frequency in patient population, in each of the datasets
we focused on the genes in the solution with the fewest number of mutations. See Table
11 for a complete list of all genes in the solution, and for the number of mutations for
each gene in each dataset. In addition to literature review, we also used DriverDBv2
[50], a database of previously discovered cancer driver genes, to further validate the
quality of QuaDMutNetEx solutions.
In the breast tumor dataset, eTNB, TP53BP1 function as a suppressor gene [94].
ATM found to be breast cancer susceptibility alleles [95]. NCOR1 identified as driver
and can be used as an independent prognostic factor for breast cancer [96, 97]. ZNF148
and SMARCA2 expression are associated with breast and other cancer types [98, 99,
100]. CCND1 is a known driver gene [97], JUN, stat3 and MYC are oncogenes [101, 102,
103]. HDAC1 is a driver and a known drug target [104, 105]. SMARCA4 is discovered
as a driver in a rare type of small cell carcinoma [106]. HSPA8 is an attractive target
for drug design and a potential risk factors and/or prognostic markers for breast cancer
[107, 108].
In the brain tumor dataset, eGBM, MEGF11 is found to be highly expressed in
GBM [109] EPHA3 is one of the most frequently mutated genes in lung cancer, it
attenuates the tumor-suppressive effects of normal EPHA3 [110]. FGFR3 plays an
important role in tumorigenesis [111].
In the ovarian tumor dataset, eHGS, PTPN11 overexpressed in ovarian cancer and
play a big rule in cell proliferation and tumorigenesis [112]. CBLB is a proto-oncogen
[113]. EGFR and MDM2 are oncogens [114, 115]. EPOR is involved in ovarian cancer
growth and angiogenesis hence can be targeted for therapy [116]. PDGFRB is a target
for tyrosine kinase inhibitor drugs [117]. Mutation in PLCG2 causes drug resistance in
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chronic lymphocytic leukemia [118]. SH2B3 acts as a signal transduction modulator in
ovarian cancers [119]. PLCG1 has a potential oncogenic role in different types of cancer
[120].
In the other breast tumor dataset, eMTB, PIK3R1 is an oncogene [121]. FKBP1C
is a pseudogene. KCNE1 regulates the activity of potassium channels and has no
obvious role in oncogensis [122].
In Pan12, which is a pool of 12 different cancer types, the genes that occur in low
frequency did not found to be oncogene or proto-oncogene.
Together, these results confirm that QuaDMutNetEx is effective in identifying
cancer driver mutations even if they are rare in the analyzed patient group.
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Table 11.: Putative driver gene sets discovered by QuaDMutNetEx. For each gene, in
parentheses, we provide the number of patients in the dataset that harbored a mutation
in that gene. Genes in bold are present in the DriverDBv2 [50] database of previously
discovered cancer drivers.
Putative driver genes Estimated
discovered by QuaDMutNetEx p-value
eTNB: Triple negative breast cancer
TP53(35) PARK2(6) SAGE1 NR3C1 (3) CREBBP NCOA1 SLC39A7
RUNX2 TAF9 HIF1A CREB5 MLL (2) TP53BP1 ATM NCOR1 ZNF148
SMARCA2 CCND1 JUN STAT3 HDAC1 SMARCA4 HSPA8 MYC (1) 0.0634
eGBM: Glioblastoma multiforme
CDKN2A(55) CDK4(18) RB1(12) MEGF11(4) EPHA3 FGFR3(3) 0.0175
eHGS: high-grade serous ovarian cancer
TP53(249) PSD3 SOS1(3) ERBB2 GRB2 PIK3R1 PTK2 UBC VAV3 ZAP70
ERBB3 NTRK2 SPRY2 JAK2(2) PTPN11 CBLB EGFR
EPOR PDGFRB PLCG2 SH2B3 SHC1 MDM2 SRC PLCG1(1) 0.001
eMTB: METABRIC breast cancer
ERBB2(84) LETM2(52) CLNS1A(37) PSG11(28) MACROD2(19) PTEN(16)
CYP24A1(16) ESPNP(13) IGF1R (10) TUBGCP5(8) EEF1A1(6) ADAMTSL4 ELF5(5)
AC116655.7-12 EGFR ZNF277(4) ANTXRL NDN PRR12(4) C4orf29
SKAP2 AE000660.1-14(3) PIK3R1 FKBP1C KCNE1(2) 0.0000
Pan12: TCGA pan-cancer of 12 cancer types
TP53(1393) PIK3CA(611) VHL(228) NPM1(65) CEBPAJ(18) ZNF672(14)
GUSBP1(9) CHMP1B MT-CO2(8) SDC4 UTS2R(7) MRC1 TREX1(6)
DNAJC19 SLC2A4RG(5) G0S2 MT1X(4)
ANXA8L1 HSPB1 KRTAP17-1 LYL1 MRPS16 ZFHX2(3) MZT2B PRAMEF14(2) 0.0000
5.4 Conclusions
In addition to to superior ability to improve on both coverage and excess coverage
of the detected driver gene sets in QuaDMutEx, QuaDMutNetEx produces results that
are more interpretable in terms of biological pathways.
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CHAPTER 6
CONCLUSIONS
6.1 Comparison between QuaDMutEx and QuaDMutNetEx
In this dissertation, I proposed two novel methods for discovering driver muta-
tions that are mutually exclusive. The first method introduced in this dissertation
was QuaDMutEx in which we followed the de novo Pathway-centric Driver Mutation
Discovery. We modeled the problem as a quadratic objective function as opposed to
classical linear objective function used in some of state-of-art methods. Additionally,
we used an efficient method for finding gene sets that minimizes the objective function
through a combination of stochastic search and exact binary quadratic programming.
QuaDMutEx also has the flexibility to adjust for the desired behavior of through pa-
rameters that control the solution size, and the trade-off between coverage and mutual
exclusivity. Flexibility helps detecting low-frequency driver genes that can be missed by
existing methods. The second method introduced in this dissertation was QuaDMut-
NetEx, in which we integrated additional terms into the objective function to represent
protein-protein interactions. Essentially, QuaDMutNetEx inherits QuaDMutEx ability
to find gene sets that have high coverage and mutually exclusive. In addition to high
coverage and mutual exclusivity, QuaDMutNetEx prefers biologically connected genes
with respect to protein-protein interaction networks. It is interesting to see how the
two methods stack up against each other.
We used two criteria to compare the two methods: a) objective function that
capture the coverage and the excess coverage that is used in Dendrix method, which is
just coverage minus coverage overlap; b) the number of connected components, which
is the number of sets of vertices in a graph that are connected to each other by paths.
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Results in Table 12 shows that QuaDMutNetEx tries to maintain the coverage and the
mutual exclusivity achieved by QuaDMutEx while minimizing the number of connected
Table 12.: Comparison between QuaDMutEx and QuaDMutNetEx. For both QuaD-
MutEx and QuaDMutNetEx, we used default parameter values k = 1 and C = 1.5
α = 0.15 unless specified otherwise.
Method Genes Coverage Excess coverage Dendrix score Connected
components
eTNB: Triple negative breast cancer
QuaDMutEx 19 0.8 0.03 73 16
QuaDMutNetEx 23 0.68 0.16 54 2
eGBM: Glioblastoma multiforme
QuaDMutEx 6 0.77 0.03 89 5
QuaDMutNetEx 6 0.77 0.03 89 3
eHGS: high-grade serous ovarian cancer
QuaDMutEx 14 0.87 0 276 12
QuaDMutNetEx 25 0.83 0.09 236 1
eMTB: METABRIC breast cancer
QuaDMutEx 18 0.43 0.10 263 18
QuaDMutNetEx 25 0.44 0.10 278 20
QuaDMutNetEx (α = 0.3) 28 0.37 0.16 212 4
Pan12: TCGA pan-cancer of 12 cancer types
QuaDMutEx 15 0.65 0.12 1870 12
QuaDMutNetEx 25 0.66 0.12 1894 20
QuaDMutNetEx (α = 0.3) 26 0.67 0.12 1903 19
QuaDMutNetEx (α = 0.6) 25 0.64 0.15 1766 2
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(a) (b)
(c) (d)
Figure 11: Effects of α on the connected components (a) eHGS run on QuaDMutEx,
(b) eHGS run on QuaDMutNetEx, (c) eGBM run on QuaDMutEx ,(d) eGBM run on
QuaDMutNetEx
components. The effect of the network term N in the big data sets, eMTB and Pan12,
was moderate. Thus, we increased α to give more weight for connectivity. As a result,
we have the desired goal of low number of connected components. Noticeably, in eGBM
dataset we have identical number of genes, coverage, excess coverage and Dendrix score,
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but a lower number of connected components, which clearly shows there is a difference
between QuaDMutEx and QuaDMutNetEx.
We can visualize the difference between the two methods in Figure 11 that shows that
the new network term N in QuaDMutNetEx has achieved its purpose. The gene sets
in QuaDMutNetEx are different from the gene sets in QuaDMutEx. Also, the gene set
in QuaDMutNetEx have fewer connected components.
Comparing two methods, there is no clear answer which one is better. De novo method
gives results that is independent from biological networks. It is an advantage if we
consider that knowledge of biological network is incomplete. More importantly, the
available data involve biases which might affect the true structure of the network in a
way that can not be measured. Hence, biological networks must be used with caution.
On the other hand, using biological network leads to better interpretability of results
especially if the network used has high quality.
6.2 Contibution of QuaDMutEx and QuaDMutNetEx
QuaDMutEx incorporates novel gene set penalty that includes non-linear penalization
of excess mutations in a single patient. Also, QuaDMutEx controls the solution size, and
has the flexibility to tradeoff between gene coverage to the patients and the exclusivity
of the coverage using the two-parameters k and C. Additionally, QuaDMutEx uses
a computationally efficient method for finding gene sets that minimize the penalty
through a combination of stochastic search and exact binary quadratic programming.
QuaDMutNetEx inherits all the functionality of QuaDMutEx and adds the feature of
biological networks rewards. In other words, QuaDMutNetEx prefers solution sets that
have adjacent genes in biological networks.
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6.3 Conclusion
In previous chapters, we showed that both methods are an improvement compared to
existing methods. QuaDMutEx and QuaDMutNetEx have a superior ability to improve
on both coverage and excess coverage of the detected driver gene sets on datasets
from different types of cancer. Additionally, QuaDMutNetEx discovers sets with a
low number of connected components. This indicates the effectiveness of both tools
in driver genes discovery for any new datasets. In particular, these two tools help in
prioritizing of putative cancer genes for further in-depth extended study. QuaDMutEx
and QuaDMutNetEx should be part of a state-of-the-art toolbox in the driver gene
discovery pipeline since both can help in detecting low-frequency driver genes that can
be missed by existing methods.
72
CHAPTER 7
FUTURE WORK
The main direction of future work could center on alternative approaches to solve the
optimization problems.
7.0.1 Genetic Algorithm
Genetic algorithm (GA) is a heuristic programming approach that mimics a simple ver-
sion of biological evolution theory towards better fitness or objective function. Typically
GA relies on the following elements: mutation, crossover, and selection. We introduced
genetic algorithm in section 3.2.1 as one of the methods to solve Unconstrained Binary
Quadratic Programs (UBQP). Here, we are proposing using the genetic algorithm to
solve our UBQP problem. We can encode the current solution as a binary genotype
whose size is equal to the total number of genes. i.e. if ith gene is 1, it indicates that
ith gene is selected to be in the solution set and vice versa. Then, we can evaluate
different fitness functions, namely, Dendrix, QuaDMutEx, and QuaDMutNetEx. Also,
we can use multi-objective optimization. In such encoding, GA operators such as mu-
tation can be easly implented in the GA’s individual representation. Genetic algorithm
is implemented efficiently in multiple off-the-shelf software such as a ”plug and play”
JCLEC software system for Evolutionary Computation (EC) research [123]. Solving
our problem using genetic algorithm is promising and might give a better objective
function value in a reasonable time.
7.0.2 Quantum annealing
Quantum computation is a new field that is currently being explored to solve certain
fundamental computational problems faster than any existing algorithms. Recently,
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quantum annealing (QA) or adiabatic quantum optimization was introduced as an
approach that potentially can outperform classical optimization algorithms. QA is
physically implemented in quantum annealing processors or D-Wave (DW) processors
[124]. Our objective function involves only pairwise terms and thus can be in principle
optimized using quantum annealing.
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